Wainua Trial Setback
AstraZeneca's Wainua trial fails heart endpoint, wiping billions from market value.
Key Points
The CARDIO-TTRansform trial was the largest ATTR-CM study to date, enrolling 1,432 patients across 130 sites in 20 countries.
AstraZeneca's shares fell about 9.55% in early trading, wiping roughly £19 billion from the company's value and placing it at the top of the FTSE 100 losers.
Market expectations had been running high for Wainua, with analysts historically modeling revenue potential around $5 billion or more, highlighting the sizable market upside anticipated prior to the readout.
The readout was framed by market observers as one of three major Phase III catalysts for AstraZeneca in the period, alongside other late-stage programs such as camizestrant and the AVANZAR lung cancer study.
AstraZeneca's experimental heart drug Wainua has failed its pivotal Phase III trial, sending the company's shares tumbling nearly 9.55% in early trading and wiping roughly £19 billion from its market value, according to Yahoo Finance. The CARDIO-TTRansform trial — the largest ATTR-CM study ever run, with 1,432 patients across 130 sites in 20 countries — found that Wainua did not reduce cardiovascular deaths and recurrent events when added to standard care.
The drug, developed with partner Ionis Pharmaceuticals, targets transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a progressive heart condition caused by misfolded proteins. The failure marks a major setback for AstraZeneca's ambitions beyond cancer, and Endpoints News described the result as an "unexpected" blow that caught markets off guard.
Why the Trial Failed to Move the Needle
The CARDIO-TTRansform trial tested Wainua on top of standard-of-care therapy, including newer stabiliser drugs already approved for ATTR-CM. That proved to be a critical problem. Patients already taking a stabiliser at baseline showed no benefit from adding Wainua. The drug essentially had no room to improve on treatments patients were already receiving.
In a prespecified subgroup of patients on Wainua alone — with no stabiliser — the drug did show a nominally significant reduction in primary cardiovascular events. But that finding was not enough to save the overall trial result. AstraZeneca and Ionis said they will present the full dataset at the European Society of Cardiology Congress for a deeper look at what the numbers mean.
£19 Billion Wiped Out in a Single Morning
AstraZeneca's stock sat at the top of the FTSE 100 losers list after the news broke, according to Market Screener. Shares fell as much as 9.9% in early trading, erasing around £20 billion in market value at the session's worst point. The drop was one of the sharpest single-day moves for the company in recent memory.
Analysts had been modeling peak sales for Wainua at $5 billion or more, making ATTR-CM one of the biggest commercial prizes in AstraZeneca's non-oncology pipeline. That estimate is now under serious review. Investors had priced in a strong chance of success, so the miss hit harder than it might have otherwise.
Standard of Care Has Moved — and Left Wainua Behind
The trial result highlights a growing problem for newer ATTR-CM drugs: the treatment landscape has improved dramatically in recent years. Stabiliser therapies like tafamidis are now widely used and effective. When a new drug is tested on top of an already-strong regimen, it becomes much harder to show added benefit.
Wainua is already approved for hereditary ATTR polyneuropathy — a nerve disease caused by the same misfolded protein — but the cardiomyopathy indication represented a far larger patient population and revenue opportunity. The company said the safety profile was consistent with prior results, meaning the drug itself was well tolerated. The issue was efficacy, not safety.
Three Big Bets Were Riding on AstraZeneca's Pipeline
Market observers had flagged CARDIO-TTRansform as one of three major Phase III readouts for AstraZeneca in this period, alongside the camizestrant breast cancer program and the AVANZAR lung cancer study. The Wainua miss now puts added pressure on those remaining catalysts to deliver.
AstraZeneca said it will continue analyzing the full dataset to understand the implications for ATTR-CM treatment. The company has built its growth story heavily around a deep pipeline beyond oncology. This result does not derail that story entirely, but it does remove what analysts had considered a near-certain blockbuster from the forecast, according to Yahoo Finance.
Sentiment
Mostly NegativePublishers
56
Articles
155
Reach
211
